A Phase II Study to Evaluate the Efficacy of IdeS (IgG Endopeptidase) to Desensitize Transplant Patients With a Positive Crossmatch Test

Trial Profile

A Phase II Study to Evaluate the Efficacy of IdeS (IgG Endopeptidase) to Desensitize Transplant Patients With a Positive Crossmatch Test

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs IdeS (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms HighIdeS
  • Sponsors Hansa Medical AB
  • Most Recent Events

    • 22 Aug 2017 Planned End Date changed from 1 Jan 2018 to 1 Jun 2018.
    • 22 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
    • 20 Jul 2017 According to a Hansa Medical media release, the company expects to enrol and treat all patients by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top